AbbVie has filed its Venclexta (venetoclax) for a new use that it hopes could change the treatment of one of the most aggressive cancers – acute myeloid leukaemia (AML).
The American Society of Clinical Oncology (ASCO) has already singled out CAR-T therapies as the most promising advance in cancer therapy this year – and latest clinical trial results from t
